
    
      This is a randomized, double-blinded, placebo-controlled study of transperineal
      intraprostatic injection of PRX302 under sonographic guidance. Subjects will be randomly
      assigned to the two treatment groups in a ratio of 2:1 between PRX302 and Placebo, stratified
      by prostate size and baseline IPSS.
    
  